Multiparameter Immunophenotyping by Flow Cytometry in Multiple Myeloma: Advantages for Diagnosis and Minimal Residual Disease Monitoring

By: G. REQUIRAND, J. MOREAUX, A. CARAUX, S. RAIMBAULT, B. KLEIN

24 September 2012


Multiple Myeloma (MM) is a B cell neoplasia characterized by the accumulation of malignant cells in the bone marrow. Immunophenotyping has become a critical tool in the management of hematological malignancies including Multiple Myeloma (MM) with an increasingly importance with diagnosis and monitoring of Minimal Residual Disease (MRD). Here, we review the advantages of Multi-parameter Flow Cytometry (MFC) to distinguish normal and malignant plasma cells, for treatment response assessment, prognostic classification and treatment management.

Download PDF (3.4 MB)